Treatment of insulin resistance with metformin in naïve genotype 1 chronic hepatitis C patients receiving peginterferon alfa-2a plus ribavirin

Hepatology

Volumn 50, Issue 6, 2009, Pages 1702-1708

  Romero Gómez, Manuel ^a   Diago, Moisés ^b   Andrade, Raúl J ^c   Calleja, José L ^d   Salmerón, Javier ^e   Fernández Rodríguez, Conrado M ^f   Solà, Ricard ^g   García Samaniego, Javier ^h   Herrerías, Juan M ⁱ   De La Mata, Manuel ^j   Moreno Otero, Ricardo ^k   Nuñez, Óscar ^l   Olveira, Antonio ^h   Durán, Santiago ^m   Planas, Ramón ^m  

^a HOSPITAL UNIVERSITARIO DE VALME   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

^c HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

^d HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^e HOSPITAL UNIVERSITARIO SAN CECILIO   (Spain)

^f HOSPITAL UNIVERSITARIO FUNDACIÓN ALCORCÓN   (Spain)

^g HOSPITAL DEL MAR   (Spain)

^h HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

ⁱ HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

^j HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^k HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^l HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^m HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

METFORMIN; PEGINTERFERON ALPHA2A; PLACEBO; RIBAVIRIN;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; GENOTYPE; HEPATITIS C; HOMEOSTASIS; HUMAN; HYPERLACTATEMIA; INSOMNIA; INSULIN RESISTANCE; INSULIN SENSITIVITY; LACTIC ACIDOSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYALGIA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE; SPAIN; VIRUS INHIBITION;

ADULT; ANTIVIRAL AGENTS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPATITIS C, CHRONIC; HUMANS; INSULIN RESISTANCE; INTERFERON ALFA-2A; MALE; METFORMIN; MIDDLE AGED; POLYETHYLENE GLYCOLS; PPAR GAMMA; RIBAVIRIN;

EID: 72549104493     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.23206     Document Type: Article

References (25)

1. Romero-Gómez M, Del Mar Viloria M, Andrade RJ, Salmerón J, Diago M, Fernández-Rodríguez CM, et al. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology 2005;128:636-641.
2. Poustchi H, Negro F, Hui J, Cua IH, Brandt LR, Kench JG, et al. Insulin resistance and response to therapy in patients infected with chronic hepatitis C virus genotypes 2 and 3. J Hepatol 2008;48:28-34.
3. Romero-Gómez M, Fernández-Rodr?́guez CM, Andrade RJ, Diago M, Alonso S, Planas R, et al. Effect of sustained virological response to treatment on the incidence of abnormal glucose values in chronic hepatitis C. J Hepatol 2008;48:721-727.
4. Sheikh MY, Choi J, Qadri I, Friedman JE, Sanyal AJ. Hepatitis C virus infection: molecular pathways to metabolic syndrome. HEPATOLOGY 2008;47:2127-2133.
5. Pazienza V, Clément S, Pugnale P, Conzelman S, Foti M, Mangia A, et al. The hepatitis C virus core protein of genotypes 3a and 1b downregulates insulin receptor substrate 1 through genotype-specific mechanisms. HEPATOLOGY 2007;45:1164-1171.
6. Shintani Y, Fujie H, Miyoshi H, Tsutsumi T, Tsukamoto K, Kimura S, et al. Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance. Gastroenterology 2004;126:840-848.
7. Boulant S, Targett-Adams P, McLauchlan J. Disrupting the association of hepatitis C virus core protein with lipid droplets correlates with a loss in production of infectious virus. J Gen Virol 2007;88:2204-2213.
8. Kahn BB, Alquier T, Carling D, Hardie DG. AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. Cell Metab 2005;1:15-25.
9. Sud A, Hui JM, Farrell GC, Bandara P, Kench JG, Fung C, et al. Improved prediction of fibrosis in chronic hepatitis C using measures of insulin resistance in a probability index. HEPATOLOGY 2004;39:1239-1247.
10. Romera M, Corpas R, Romero-Gomez M. Insulin resistance as a noninvasive method for the assessment of fibrosis in patients with hepatitis C: a comparative study of biochemical methods. Rev Esp Enferm Dig 2006; 98:161-169.
11. Bailey CJ, Path MRC, Turner RC. Metformin. N Engl J Med 1996;334; 574-579.
12. Nakatani Y, Kaneto H, Kawamori D, Yoshiuchi K, Hatazaki M, Matsuoka TA,et al. Involvement of endoplasmic reticulum stress in insulin resistance and diabetes. J Biol Chem 2005;280:847-851.
13. Korenaga M, Wang T, Li Y, Showalter LA, Chan T, Sun J, et al. Hepatitis C virus core protein inhibits mitochondrial electron transport and increases reactive oxygen species (ROS) production. J Biol Chem 2005;280: 37481-488.
14. Holland W, Morrison T, Chang Y, Wiernsperger N, Stith BJ. Metformin (Glucophage) inhibits tyrosine phosphatase activity to stimulate the insulin receptor tyrosine kinase. Biochem Pharmacol 2004;67:2081-2091.
15. Xie Z, Dong Y, Scholz R, Neumann D, Zou MH. Phosphorylation of LKB1 at serine 428 by protein kinase C-zeta is required for metforminenhanced activation of the AMP-activated protein kinase in endothelial cells. Circulation 2008;117:952-962.
16. Overbeck K, Genné D, Golay A, Negro F, Swiss Association for the Study of the Liver (SASL). Pioglitazone in chronic hepatitis C not responding to pegylated interferon-alpha and ribavirin. J Hepatol 2008;49:295-298.
17. Conjeevaram H, Burant CF, McKenna B, Harsh D, Kang H, Das AK, et al. A randomized, double-blind, placebo-controlled study of PPARgamma agonist pioglitazone given in combination with peginterferon and ribavirin in patients with genotype-1 chronic hepatitis C [Abstract].HEPATOLOGY 2008;48(Suppl):384A.
18. Elgouhari HM, Cesario KB, Lopez R, Zein NN. Pioglitazone improves early virologic kinetic response to PEGIFN/RBV combination therapy in hepatitis C genotype 1 naïve patients. HEPATOLOGY 2008;48(Suppl): 383A.
19. Wang CC, Krantz E, Klarquist J, Krows M, McBride L, Scott EP, et al. Acute hepatitis C in a contemporary US cohort: modes of acquisition and factors influencing viral clearance. J Infect Dis 2007;196:1474-1482.
20. Yoshida M, Jacques PF, Meigs JB, Saltzman E, Shea MK, Gundberg C,et al. Effect of vitamin K supplementation on insulin resistance in older men and women. Diabetes Care 2008;31:2092-2096.
21. Love-Osborne K, Sheeder J, Zeitler P. Addition of metformin to a lifestyle modification program in adolescents with insulin resistance. J Pediatr 2008;152:817-822.
22. Tuthill A, McKenna MJ, O'Shea D, McKenna TJ. Weight changes in type 2 diabetes and the impact of gender. Diabetes Obes Metab 2008;10:726-732.
23. Legro RS, Barnhart HX, Schlaff WD, Carr BR, Diamond MP, Carson SA,et al. Ovulatory response to treatment of polycystic ovary syndrome is associated with a polymorphism in the STK11 gene. J Clin Endocrinol Metab 2008;93:792-800.
24. Mehenni H, Resta N, Park JG, Miyaki M, Guanti G, Costanza MC. Cancer risks in LKB1 germline mutation carriers. Gut 2006;55:984-990.
25. Salpeter S, Greyber E, Pasternak G, Salpeter E. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev 2006;1:CD002967.